Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: J Invest Dermatol. 2011 Dec 8;132(2):410–420. doi: 10.1038/jid.2011.335

Figure 3. 4-F-GlcNAc treatment blunts melanoma growth and interferes with Gal-1-binding to T and NK cells.

Figure 3

(a) Tumor growth was assayed in mice inoculated with B16 cells and treated with 4-F-GlcNAc or control, starting from days 1 or 9 (n=15/group). (b) Tumor masses (mean ± SD) were calculated on day 17 for each mouse group. (c) Melanoma-infiltrating T cells were quantified in 8 non-overlapping 20× fields from control or 4-F-GlcNAc-treated mice (n=4). (d) Percentage of melanoma-infiltrating T cells binding Gal-1hFc were quantified. (e) Cells from melanoma-draining LNs of 4-F-GlcNAc or control-treated mice were gated on TCR-β and analyzed for CD8 expression and Gal-1hFc binding or gated on TCR-β(−) cells and analyzed for NK1.1 expression and Gal-1hFc binding by flow cytometry. Statistically significant differences compared with control treatments on day 17 by Student’s paired t-test, *p<0.01 and **p<0.001. Data represents mean ± SD of 3 independent experiments.